Jim Cramer shares stock market news about buying Regeneron stock, the Bristol Meyers deal, and Trump’s tweet about a stimulus package.

MyoKardia, Eidos Therapeutics, HMS Holding, Aphria and Jen-Weld are five of Monday's top gainers.

Stocks end higher after President Trump tweets he's leaving Walter Reed Medical Center on Monday evening.

MyoKardia is surging after a takeout deal from Bristol-Myers Squibb, which is marginally higher on the day. Does the deal make Bristol-Myers a buy?

Gilead Sciences is starting the week off with a solid gain. Can bulls take control and drive shares higher?

MydoKardia's experimental heart treatment, Mavacamten, was granted a "breakthrough therapy designation' from the U.S. Food & Drug Administration in July of this year.

Moderna only went public in December, and is already creating a buzz.

Jim Cramer says we actually want some bad news because definitive weaker news now drives stocks up and strong news takes them down.

Jim Cramer looks at the high-flying FANG stocks, and says he likes these companies best when their prices return to earth.

Roku's eroding market share, and its need for new investment, will pressure near-term profits, according to KeyBanc analyst Justin Patterson.

“Our investor survey reinforces our views that Elon Musk's recent involvement with Twitter has contributed to negative sentiment momentum in Tesla shares," said Morgan Stanley analyst Adam Jonas.

Mobile carrier companies are always eager to increase revenue through fees customers pay and to outflank their competition with deals.